Users Online: 88
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others


Crizotinib: A comprehensive review

Sahu Arvind, Prabhash Kumar, Noronha Vanita, Joshi Amit, Desai Saral

Year : 2013| Volume: 2| Issue : 2 | Page no: 91-97

   This article has been cited by
1 Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer
Candice C. Poon,John J. Kelly
International Journal of Cancer. 2017;
[Pubmed]  [Google Scholar] [DOI]
2 Synergism between ivermectin and the tyrosine kinase/P-glycoprotein inhibitor crizotinib against Haemonchus contortus larvae in vitro
Ali Raza,Steven R. Kopp,Andrew C. Kotze
Veterinary Parasitology. 2016; 227: 64
[Pubmed]  [Google Scholar] [DOI]
3 Crizotinib: from discovery to accelerated development to front-line treatment
F. Blackhall,F. Cappuzzo
Annals of Oncology. 2016; 27(suppl_3): iii35
[Pubmed]  [Google Scholar] [DOI]
4 ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer
Haiyan Sun,Christopher G. England,Reinier Hernandez,Stephen A. Graves,Rebecca L. Majewski,Anyanee Kamkaew,Dawei Jiang,Todd E. Barnhart,Yunan Yang,Weibo Cai
European Journal of Nuclear Medicine and Molecular Imaging. 2016;
[Pubmed]  [Google Scholar] [DOI]
5 Pharmacogenomics and targeted therapy of Cancer: Focusing on Non-small cell lung Cancer
Seyyed Mortaza Haghgoo,Abdolamir Allameh,Esmaeil Mortaz,Johan Garssen,Gert Folkerts,Peter J. Barnes,Ian M. Adcock
European Journal of Pharmacology. 2015;
[Pubmed]  [Google Scholar] [DOI]
6 A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
Alana Dikopf,Kevin Wood,Ravi Salgia
Expert Opinion on Drug Safety. 2015; 14(3): 485
[Pubmed]  [Google Scholar] [DOI]
Amro Abdellatief,Julian R. Molina,Jose S. Pulido
Retinal Cases & Brief Reports. 2015; : 1
[Pubmed]  [Google Scholar] [DOI]
8 Precision medicine in oncology drug development: a pharma perspective
Simon J. Hollingsworth
Drug Discovery Today. 2015; 20(12): 1455
[Pubmed]  [Google Scholar] [DOI]
9 Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification
Matthew G. Hanna,Vesna Najfeld,Hanna Y. Irie,Joseph Tripodi,Anupma Nayak
SpringerPlus. 2015; 4(1)
[Pubmed]  [Google Scholar] [DOI]
10 AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Samuel H. Myers,Valerie G. Brunton,Asier Unciti-Broceta
Journal of Medicinal Chemistry. 2015;
[Pubmed]  [Google Scholar] [DOI]
11 Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth
Coralie Hoareau-Aveilla,Thibaud Valentin,Camille Daugrois,Cathy Quelen,Géraldine Mitou,Samuel Quentin,Jinsong Jia,Salvatore Spicuglia,Pierre Ferrier,Monica Ceccon,Sylvie Giuriato,Carlo Gambacorti-Passerini,Pierre Brousset,Laurence Lamant,Fabienne Meggetto
Journal of Clinical Investigation. 2015; 125(9): 3505
[Pubmed]  [Google Scholar] [DOI]
12 Molecular biomarkers in clinical development: what could we learn from the clinical trial registry?
Avisek Deyati,Rama Devi Sanam,Sreenivasa Rao Guggilla,Vijaya Rao Pidugu,Natalia Novac
Personalized Medicine. 2014; 11(4): 381
[Pubmed]  [Google Scholar] [DOI]
13 Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery
Wen-Chieh Wang,Hui-Yi Shiao,Chieh-Chien Lee,Ka-Shu Fung,Hsing-Pang Hsieh
MedChemComm. 2014; 5(9): 1266
[Pubmed]  [Google Scholar] [DOI]


Read this article